Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Blaine Broussard

Internal Medicine Alexandria, LA Medical Doctor

NPI 1023251659 CMS profile 182166

176 Versailles Blvd, Alexandria, LA 71303

Open in the dashboard

General payments

$5,709

389 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Blaine Broussard of Alexandria, LA is reported in the CMS Open Payments database as having received $5,709 across 389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,126 69
2024 General $1,266 76
2023 General $849 55
2022 General $803 56
2021 General $675 50
2020 General $524 41
2019 General $464 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Blaine Broussard
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Blaine Broussard were reported at $1,126. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Blaine Broussard Internal Medicine median Middle half National median
2019 $464 $159 $48–$570 $163
2020 $524 $119 $33–$402 $114
2021 $675 $135 $37–$521 $132
2022 $803 $141 $42–$496 $149
2023 $849 $149 $45–$519 $160
2024 $1,266 $154 $47–$537 $164
2025 $1,126 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,901 138 payments
  2. Novo Nordisk Inc $804 57 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $411 22 payments
  4. AstraZeneca Pharmaceuticals LP $409 25 payments
  5. Pfizer Inc. $358 32 payments
  6. Axsome Therapeutics, Inc. $293 17 payments
  7. Amgen Inc. $234 15 payments
  8. Otsuka America Pharmaceutical, Inc. $184 9 payments
  9. Lilly USA, LLC $178 12 payments
  10. Allergan Inc. $140 14 payments
  11. Other $798 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,709 389 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $839 58 payments
  2. UBRELVY $814 50 payments
  3. Ozempic $525 37 payments
  4. VRAYLAR $359 32 payments
  5. RYBELSUS $346 24 payments
  6. TRINTELLIX $337 18 payments
  7. Auvelity $293 17 payments
  8. ELIQUIS $252 22 payments
  9. REXULTI $184 9 payments
  10. Wegovy $165 11 payments
  11. Other $2,642 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 208 drugs

Part D claims

14,808

Median for Internal Medicine: 777

Drug cost

$1,303,473

Median for Internal Medicine: $73,373

Branded share of claims

24%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 157 $176,842
Eliquis Apixaban Brand 143 $132,100
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 118 $105,140
Trulicity Dulaglutide Brand 54 $75,385
Mounjaro Tirzepatide Brand 58 $75,135
Januvia Sitagliptin Phosphate Brand 80 $74,447
Jardiance Empagliflozin Brand 62 $56,486
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 43 $54,171
Tresiba Flextouch U-100 Insulin Degludec Brand 43 $39,373
Linzess Linaclotide Brand 49 $38,724

The 10 drugs with the highest cost, of 208 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$260,627

Of which drugs: $92

Medicare patients

711

Average age 74

Services billed

9,689

405 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 39%
Diabetes 33%
Chronic kidney disease 28%
Atrial fibrillation 23%
Heart failure 22%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 107 $76

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $347
$347 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $137
$137 17 —
UBRELVY
  • AbbVie, Inc. $128
$128 — —
Auvelity
  • Axsome Therapeutics, Inc. $89
$89 — —
VRAYLAR
  • AbbVie, Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record